Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02955290 · ClinicalTrials.gov registry record · Phase 1

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

A Phase 1 study of Lung Non-Small Cell Carcinoma and Stage III Lung Cancer AJCC v8, sponsored by Roswell Park Cancer Institute.

Active
Registry status
Phase 1
Development phase
51
Enrollment target
5
Study locations

NCT02955290: Active Phase 1 study of Lung Non-Small Cell Carcinoma and Stage III Lung Cancer AJCC v8, sponsored by Roswell Park Cancer Institute.

NCT02955290 is a Phase 1 study of Lung Non-Small Cell Carcinoma and Stage III Lung Cancer AJCC v8 that is active but no longer recruiting, run by Roswell Park Cancer Institute. The registered enrollment target is 51 participants, below the 159-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (68% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02955290, a Phase 1 study of Lung Non-Small Cell Carcinoma and Stage III Lung Cancer AJCC v8, is active but no longer recruiting, sponsored by Roswell Park Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
51 participants
Enrollment target
5
Study locations

Study Summary

This phase I/II trial studies the best dose and side effects of recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax) and nivolumab and to see how well they work in treating patients with non-small cell lung cancer or squamous head and neck cancer that has spread to other places in the body. Vaccine therapy, such as CIMAvax vaccine may help slow down and stop tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CIMAvax vaccine together with nivolumab or pembrolizumab may work better in treating patients with non-small cell lung cancer or squamous head and neck cancer.

Primary Outcome

No formal analyses of DLTs are planned. Presentation of DLTs will be limited to DLT-evaluable patients.

Conditions Studied

Lung Non-Small Cell Carcinoma Stage III Lung Cancer AJCC v8 Metastatic Lung Non-Small Cell Carcinoma Stage IIIB Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Recurrent Head and Neck Squamous Cell Carcinoma Stage IIIC Lung Cancer AJCC v8 Advanced Head and Neck Squamous Cell Carcinoma Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 PD-L1 Positive

Interventions

  • BIOLOGICAL Pembrolizumab
  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Nivolumab
  • BIOLOGICAL Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

Study Locations (5)

New York

  • Roswell Park Cancer Institute - Buffalo
  • St. Francis Hospital - Roslyn
  • Good Samaritan Hospital - West Islip

Indiana

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2016-12-22
Est. Completion 2027-12-09
Phase Phase 1
Roswell Park Cancer Institute

365 total trials

What the registry record for NCT02955290 still lists

NCT02955290 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 159-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (68% lower).

The record links to 10 conditions, with Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT02955290 lists 5 locations in 3 states (New York, Indiana, Ohio).

Frequently Asked Questions

What is clinical trial NCT02955290 about?

NCT02955290 is a clinical study titled "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer". This phase I/II trial studies the best dose and side effects of recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax) and nivolumab and to see how well they work in treating patients with non-small cell lung cancer or squamous head and neck cancer that has spread to other places in the body...

What is the current status of trial NCT02955290?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2016-12-22. Estimated completion is 2027-12-09.

What conditions does trial NCT02955290 study?

This clinical trial studies the following conditions: Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8.

What interventions are being tested in trial NCT02955290?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL), Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT02955290?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02955290 being conducted?

This trial has 5 study locations across Indiana, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Non-Small Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02955290's enrollment target sits among peer trials

51 22nd of 47 higher than 26 of 47 other Lung Non-Small Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Non-Small Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02701153 · 51 participants · NA

    Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

  • NCT03663790 · 51 participants · NA

    Effects of Gait Retraining on Lower Extremity Biomechanics

  • NCT03874052 · 51 participants · Phase 1

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • NCT04704661 · 51 participants · Phase 1

    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02955290, the US trial registry maintained by the National Library of Medicine. NCT02955290 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.